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Abstract We investigated the effects of bFGF and TGF-L on
the expression of type XVI collagen, a member of the fibril
associated collagen family, in human dermal fibroblasts and
arterial smooth muscle cells. We found that bFGF decreased the
K1(XVI) collagen mRNA to 18^24% of the controls, while TGF-
L increased the mRNA to 150^360%. Immunoprecipitation of
metabolically labeled cells revealed corresponding, but less
pronounced, changes at the protein levels. The results suggested
that type XVI collagen expression is regulated by bFGF and
TGF-L in a manner similar to their regulation of the major type I
fibrillar collagen produced by these cells.
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1. Introduction
Type XVI collagen is a minor collagen initially identi¢ed by
cDNA cloning of the K1(XVI) collagen chain from human
¢broblast and placenta cDNA libraries [1,2]. The deduced
primary structure of the K1(XVI) collagen chain possesses
structural features common to the family of ¢bril-associated
collagens with interrupted triple-helices (FACIT) [3,4]. Mem-
bers of this family, collagens type IX, XII, and XIV, localize
on the surface of either type I or type II collagen ¢brils [5].
Subsequent immunoprecipitation experiments show that the
K1(XVI) collagen polypeptide of 220 kDa is synthesized and
secreted as a homotrimer by dermal ¢broblasts and arterial
smooth muscle cells [6]. However, it is not known if type XVI
collagen, as its structure suggests, colocalizes with the major
collagen ¢brils consisting of type I and III collagens deposited
by these two cell types.
Cytokines and growth factors play important roles in reg-
ulating collagen synthesis during normal and pathological
conditions [7]. Transforming growth factor-L (TGF-L) is a
particularly important regulator of collagen synthesis [8]. It
upregulates collagen gene expression during wound repair,
and causes the abnormal accumulation that characterizes tis-
sue ¢brosis. Basic ¢broblast growth factor (bFGF), a heparin-
binding growth factor, stimulates vascular smooth muscle cell
proliferation and migration following vascular injury. Depo-
sition of collagen by arterial smooth muscle cells is considered
to be a major contribution to the formation of arteriosclerotic
plaques [9]. The autocrine TGF-L activity is thought to be
responsible for elevated collagen synthesis by the proliferating
smooth muscle cells [10]. However, bFGF exerts the opposite
e¡ect on collagen synthesis by downregulating type I collagen
synthesis in arterial smooth muscle cells [11] and in dermal
¢broblasts [12].
Little is known about the regulation of type XVI collagen
gene expression. To investigate whether it is regulated simi-
larly to the major ¢brillar collagens, we examined the e¡ects
of bFGF and TGF-L on the expression of type XVI collagen
mRNA and protein.
2. Materials and methods
2.1. Growth factors and cell cultures
Simian recombinant TGF-L2 was a generous gift from Dr. David
R. Olsen, Celtrix Laboratories, Santa Clara, CA, USA. bFGF was
purchased from Intergen (Purchase, NY, USA).
Human dermal ¢broblasts, established from breast tissue of normal
individuals of the same age-group after reduction surgery, were grown
in Dulbecco’s modi¢ed Eagle’s medium (DMEM, Gibco-BRL) sup-
plemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin
and 100 Wg/ml streptomycin sulfate (Gibco-BRL). Arterial smooth
muscle cells, established from adult iliac arteries from brain-dead,
heart-beating individuals [11], were grown in Medium 199 (Gibco-
BRL), supplemented with 10% FBS, 2 mmol/l glutamine, 200 U/ml
penicillin, and 200 Wg/ml streptomycin in £asks coated with 0.1%
gelatin. All cells were grown at 37‡C under 5% CO2.
Subcon£uent ¢broblasts and smooth muscle cells were treated with
10 ng/ml TGF-L2 in their respective media supplemented with 0.5%
FBS, or with 50 ng/ml bFGF in media containing 3% FBS.
2.2. RNA extraction and Northern blot analysis
Total RNA was extracted using the RNeasy kit from Quiagen (CA,
USA). Twenty Wg of total RNA was loaded onto 1% formaldehyde-
agarose gels, electrophoretically separated, and transferred onto nylon
membranes (Amersham) by standard methods [13]. The membranes
were hybridized with a [32P]dCTP labeled 4.0-kb K1(XVI) collagen
cDNA probe, F352 [1], as described [13]. RNA was stained with
ethidium bromide, photographed, and quanti¢ed by densitometric
analysis (Bio-Rad, CA, USA) for evaluation of RNA loading di¡er-
ences. Quantitative evaluation of K1(XVI) collagen expression was
obtained by exposing ¢lters to phospho-storage screens and by sub-
sequent scanning with the phospho-imaging system Si 445 (Molecular
Dynamics, CA, USA).
2.3. Metabolic labeling and immunoprecipitation
Cells grown in 35-mm dishes were washed twice with phosphate
bu¡ered saline (PBS), and then metabolically labeled for 4 h with
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40 WCi/dish of [35S]Cys (s 1000 Ci/mmol; Amersham) in 0.8 ml of
de¢cient DMEM (without FBS, sodium pyruvate, L-methionine and
L-cysteine) containing 50 Wg/ml ascorbic acid, with or without 50 ng/
ml bFGF or 10 ng/ml TGF-L2. Following the labeling period, the
culture medium was collected, and 200 Wl 5U immunomix bu¡er
supplemented with protease inhibitors [6] was added and the mix
incubated on ice for 30 min. Cell layers were washed twice with
PBS, and then extracted with 1 ml of 1U immunomix with protease
inhibitors and 0.1% SDS on ice for 30 min. After removing the soluble
cytoplasmic extract (cell), the remaining extracellular matrix (ECM)
was solubilized by incubating on ice for 30 min in 0.5 ml PBS con-
taining 6 M urea, then was frozen, thawed, and centrifuged to remove
the insoluble material. The supernatant was adjusted to 1 ml with 1U
immunomix and protease inhibitors. For immunoprecipitation, 500-Wl
aliquots were precleared with 10 Wl protein A agarose, and incubated
for 2 h at 4‡C with 10 Wl rabbit antiserum, speci¢c for the NC11
domain of the K1(XVI) collagen chain [14]. The immunoprecipitated
material was washed as previously described [6], except for an addi-
tional wash with 0.75 ml bu¡er containing 10 mM Tris-HCl, pH 8.5,
0.6 M NaCl, 0.1% SDS, 0.05% NP-40 after the second washing step.
The immunoprecipitated material was separated on 4^15% SDS-poly-
acrylamide gradient gels (Ready gel, Bio-Rad) and run at 40 mA for
45 min. Gels were ¢xed in a solution of 45% methanol/15% acetic
acid, immersed in autoradiography enhancer solution (DuPont-
NEN), dried and subjected to £uorography at 370‡C.
3. Results
3.1. Basic FGF and TGF-L modulate steady state levels of the
K1(XVI) collagen mRNA in arterial smooth muscle cells
and in dermal ¢broblasts
Human arterial smooth muscle cells were treated for in-
creasing time periods with 50 ng/ml bFGF, a dose that pre-
viously was shown to exert the maximal e¡ect on type I col-
lagen gene expression [11]. Total RNA was prepared from the
control and treated cultures at 24, 48, 72, and 96 h, and was
subjected to Northern blot analysis for the K1(XVI) collagen
mRNA. As shown in Fig. 1, the steady state levels of the 5.5-
kb K1(XVI) collagen mRNA were down-regulated by bFGF
in a time dependent manner. A detectable decrease was ob-
served after 24 h of the bFGF treatment and the mRNA
levels were reduced signi¢cantly after 48^96 h. Treatment of
human dermal ¢broblasts with bFGF produced a similar re-
sult. The degree of inhibition in both cell types was quanti¢ed
by densitometric analysis of 2^4 separate Northern blots.
Maximal inhibition to 18^24% of the control levels were ob-
served after 72 h of bFGF treatment (Fig. 2A).
To determine the e¡ect of TGF-L on K1(XVI) collagen
mRNA expression, arterial smooth muscle cells and dermal
¢broblasts were treated with 10 ng/ml TGF-L2 for 6, 12, 24,
and 48 h. TGF-L caused an increase in the steady state
mRNA levels in both cell types. The increase was detectable
as early as 6 h after treatment, and maximal induction was
observed 24 h after treatment (Fig. 2B). The induction was
more pronounced in smooth muscle cells (360%) than in der-
mal ¢broblasts (150%).
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Fig. 1. A: A representative Northern blot analysis of total RNA
from human arterial smooth muscle cells treated with 50 ng/ml
bFGF. Twenty Wg per lane total RNA was hybridized with a 4.0-kb
K1(XVI) collagen cDNA probe, F352, resulting in speci¢c binding
to the 5.5-kb type XVI collagen mRNA. RNA isolated from cells
treated without (lanes 1, 3, 5, 7) and with 50 ng/ml bFGF (lanes 2,
4, 6, 8) for either 24 h (lanes 1, 2), 48 h (lanes 3, 4), 72 h (lanes 5,
6) or 96 h (lanes 7, 8). B: Ethidium bromide staining of the 28S
and 18S ribosomal RNA as controls for RNA loading. Filters were
exposed to phospho-storage screens overnight and analyzed by scan-
ning with the phospho-imaging system SI 445.
Fig. 2. Relative changes of K1(XVI) mRNA expression in response
to bFGF (panel A) and TGF-L (panel B) at di¡erent time points.
Northern ¢lters were exposed overnight to phospho-storage screens
and analyzed by phospho-imaging. The levels of K1(XVI) collagen
mRNA were normalized to the 28S rRNA stained with ethidium
bromide. Data represent the mean þ standard deviation of 3 or 4
separate Northern blots, and are expressed as percent of controls,
arbitrarily set at 100%. Solid symbols denote dermal ¢broblasts,
and open symbols denote arterial smooth muscle cells.
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3.2. Basic FGF and TGF-L modulate collagen type XVI protein
biosynthesis
Cells were metabolically labeled during the ¢nal 4 h of the
treatment to investigate if these two growth factors cause the
corresponding changes in the K1(XVI) collagen protein pro-
duction. The medium, cell, and ECM extracts were immuno-
precipitated with an antibody speci¢c for the N-terminal do-
main NC11 [14] and analyzed by gel electrophoresis. There
was essentially no change in the amount of total protein syn-
thesis in all three fractions when cells with and without treat-
ment were compared (data not shown). Incubation of ¢bro-
blasts with bFGF resulted in an approximately 20% decrease
in the 220-kDa band, corresponding to the migration of the
K1(XVI) collagen chain in the cell and in ECM, but a negli-
gible decrease in the medium (Fig. 3B, Fig. 4A). When
smooth muscle cells were treated with bFGF, the ECM and
medium fractions displayed a 20% decrease in the 220-kDa
band, but this band in the cell extract was very faint (Fig. 3A,
Fig. 4A). Instead, a more prominent 180-kDa band appeared.
This band previously was noted in smooth muscle cells
and could be a partially degraded K1(XVI) collagen chain
[6]. The antibody also precipitated an 85-kDa polypeptide,
which was thought to be unrelated to the K1(XVI) collagen
chain [6].
Administration of TGF-L to both smooth muscle cells and
to ¢broblasts for 24 h led to a marked increase in the 220-kDa
band in cell and in ECM extracts, while only a moderate
increase was observed in the media (Fig. 3C,D, Fig. 4B).
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Fig. 3. SDS-PAGE analysis of cell, ECM and medium extracts immunoprecipitated with the K1(XVI) collagen speci¢c NC 11 antiserum. A:
Human arterial smooth muscle cells treated with 50 ng/ml bFGF for 96 h (lanes 2, 4, 6) and untreated control samples (lanes 1, 3, 5). B: Hu-
man dermal ¢broblasts treated with 50 ng/ml bFGF for 72 h (lanes, 2, 4, 6) and untreated control samples (lanes 1, 3, 5). C: Human arterial
smooth muscle cells treated with 10 ng/ml TGF-L for 24 h (lanes 2, 4, 6) and untreated control samples (lanes 1, 3, 5). D: Human dermal ¢-
broblasts treated with 10 ng/ml TGF-L for 24 h (lanes 2, 4, 6) and untreated control samples (lanes 1, 3, 5). In all panels, cell extracts are ana-
lyzed in lanes 1, 2; ECM extracts are shown in lanes 3, 4 and medium extracts are separated in lanes 5, 6. Arrows denote the 220-kDa
K1(XVI) collagen speci¢c band. Gels were subjected to autoradiography for 12 h (panel A), 18.5 h (panel B), 9.5 h (panel C) and 6.5 h (panel
D) at 370‡C.
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4. Discussion
We demonstrate in this study that TGF-L causes an in-
crease in the steady state level of K1(XVI) collagen mRNA
in dermal ¢broblasts and in smooth muscle cells, while bFGF
elicits the opposite e¡ect in both cells. The modulation of
mRNA by these two growth factors followed di¡erent time
courses. bFGF exerts substantial e¡ects after 48 h of treat-
ment, while TGF-L exhibits a more rapid response in that an
incubation time of 12^24 h results in maximal stimulation.
Similar time courses have been reported for these two growth
factors on type I collagen gene expression [11]. Thus, there
appears to be a coordinate regulation between type XVI col-
lagen, a member of the FACIT collagen family, and the major
type I ¢brillar collagen synthesized by ¢broblasts and smooth
muscle cells. It has been shown recently that bFGF upregu-
lates collagenase gene expression within 24 h of treatment [11],
and the e¡ect is exerted at the transcriptional level through an
AP-1 consensus sequence in its promoter [15]. This suggests
that the bFGF e¡ects on types XVI and I collagen expression
may be secondary to initial events triggered by the growth
factor, which are mediated through high a⁄nity transmem-
brane FGF receptors with tyrosine kinase activity and lower
a⁄nity binding of bFGF to cell surface proteoglycans [16].
TGF-L is a potent stimulator of various collagen types,
including types I, III, V, XI ¢brillar collagens, and types IV,
VI, VII non-¢brillar collagens [17^21]. TGF-L acts primarily
at the transcriptional level and transcription factors NF-1,
Sp1, AP-1 and TBE have been implicated in mediating its
action [22^25]. Our results with type XVI collagen add anoth-
er example to the repertoire of collagens upregulated by TGF-
L. Whether type XVI collagen is regulated at the transcrip-
tional level remains to be determined.
Upregulation of the K1(XVI) collagen mRNA by TGF-L is
re£ected at the protein levels in the cell and in ECM extract,
but not in the medium. The lack of corresponding response in
the medium may be explained by the short labeling time of the
experiments. Downregulation of the K1(XVI) collagen expres-
sion by bFGF is less pronounced at the protein than at the
mRNA level. This suggests that post-transcriptional mecha-
nisms such as translational control or protein stability may
play a role in regulating type XVI collagen protein expression.
TGF-L and bFGF elicit diverse e¡ects on extracellular ma-
trix gene expression in a variety of cell types in both normal
and pathological conditions. We recently detected substantial
synthesis of collagen type XVI in other cell types such as
chondrocytes and keratinocytes (Graºssel et al., in prepara-
tion). We also localized, by indirect immuno£uorescence,
type XVI collagen expression in the dermal-epidermal junc-
tion of skin and blood vessels of heart tissue. Collectively, the
data suggest that type XVI collagen participates with ¢brillar
collagens in the development and maintenance of various
types of connective tissues. Further investigation of collagen
XVI regulation is needed to clarify the role of this FACIT
collagen member in pathogenesis of connective tissue diseases.
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